{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T16:36:33Z","timestamp":1721061393246},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.12788\/cutis.0775","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T14:24:44Z","timestamp":1686061484000},"source":"Crossref","is-referenced-by-count":3,"title":["Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma"],"prefix":"10.12788","volume":"111","author":[{"given":"Danielle Y","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","container-title":["Cutis"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/CT111005013_e.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T14:24:45Z","timestamp":1686061485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/dermatology\/article\/262985\/melanoma\/eruptive-keratoacanthomas-after-nivolumab-treatment-stage-iii"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"URL":"https:\/\/doi.org\/10.12788\/cutis.0775","relation":{},"subject":[],"published":{"date-parts":[[2023,5]]}}}